Phase 2 clinical trial of primary systemic therapy for primary breast cancer Sequential regimen of Nab-Paclitaxel followed by EC for HER2 negative breast cancer and concurrent regimen of Docetaxel/Carboplatin/Herceptin for HER2 positive breast cancer
Phase 2
Recruiting
- Conditions
- Primary breast cancer
- Registration Number
- JPRN-UMIN000013513
- Lead Sponsor
- Dept of breast oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are ineligible for chemotherapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of pathological complete response
- Secondary Outcome Measures
Name Time Method Postsurgical histological response, Rate of breast conservative surgery, clinical response, and adverse effect DFS and overall survival Exploratory study of imaing and molecular biomarkers